Neoadjuvant α–PD-1/α–CTLA4 therapy using HNSCC samples from the IMCISION trial identified a decrease in activated Tregs and dysfunctional CD8+ T cells (157). The gene discussed is CTLA4; the disease is head and neck squamous cell carcinoma.